Similarly, a polymer-based DDS for Tim-3 siRNA and sorafenib exhibited improved tumor targeting, immune response enhancement, and a 50% reduction in tumor volume compared to standard therapies [218,221]. The gene discussed is HAVCR2; the disease is neoplasm.